Search

Displaying results 3651 - 3660 of 8412 in total
  1. Drug

    Streptococcus pneumoniae type 11a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10330
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Streptococcus pneumoniae type 14 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10332
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  3. Drug

    Streptococcus pneumoniae type 18c capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10335
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  4. Drug

    Streptococcus pneumoniae type 20 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10338
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  5. Drug

    Streptococcus pneumoniae type 22f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10339
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  6. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  7. Drug

    SL017

    go.drugbank.com/drugs/DB05156
    Experimental

    SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis

  8. Drug

    Firuglipel

    go.drugbank.com/drugs/DB19506
    Investigational

    Firuglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).

  9. Drug

    Orgotein

    go.drugbank.com/drugs/DB11444
    ExperimentalVet approved

    Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen. … Hydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum.

  10. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant has a monoisotopic molecular weight of 462.09 Da. … Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).